A Promising but Controversial New Depression Treatment Is Now More Accessible in Vermont
A primary care doctor at the University of Vermont Health Network will soon start treating depression with a mind-altering drug that’s shown promise in helping people who don’t respond to traditional medicine.
The medication — known as esketamine and sold by Johnson & Johnson under the brand name Spravato — is chemically similar to ketamine, a substance that’s been used in medical settings as an anesthetic, on the streets as a party drug and, more recently, as an off-label treatment for mood disorders.
438 total views
